CVR: 41557958
DKK 25,842,285
Gross profit
Net result: DKK -8,054,390
No owners listed
CVR · view ownership and management
Director role ended: Søren Sylvester Skjærbæk
CVR · 15/12/2023
View the full event history
Dragonfly Therapeutics CPH ApS was a Danish company of the type Anpartsselskab based in Ballerup, founded in 2020 and dissolved in 2023. The company was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi. In 2022, the company reported a gross profit of DKK 25,842,285 and a net result of DKK -8,054,390. Equity in the 2022 report amounted to DKK -5,948,458.
Screen owners and management against the Danish FSA's official PEP lists
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationNo. Dragonfly Therapeutics CPH ApS is registered in the Danish CVR register with the status Dissolved and ceased on 15 December 2023.
Dragonfly Therapeutics CPH ApS was founded on 29 July 2020.
Dragonfly Therapeutics CPH ApS was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi (industry code 721100).
In 2022, Dragonfly Therapeutics CPH ApS reported a gross profit of DKK 25,842,285.
Dragonfly Therapeutics CPH ApS was located at Baltorpvej 154, 2750 Ballerup.
The CVR number of Dragonfly Therapeutics CPH ApS is 41557958.
As of December 15, 2023, Attent Statsautoriseret Revisionsanpartsselskab has stepped down as auditor of Dragonfly Therapeutics CPH ApS.
As of December 15, 2023, Søren Sylvester Skjærbæk has stepped down as liquidator of Dragonfly Therapeutics CPH ApS.
On December 15, 2023, Dragonfly Therapeutics CPH ApS exited liquidation.
Dragonfly Therapeutics CPH ApS was dissolved on December 15, 2023.
Dragonfly Therapeutics CPH ApS has published its annual report for 2022. Gross profit came to DKK 25,842,285, and the net result was DKK -8,054,390.
As of November 9, 2022, Attent Statsautoriseret Revisionsanpartsselskab has been appointed auditor of Dragonfly Therapeutics CPH ApS.
As of November 9, 2022, RSM DANMARK STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Dragonfly Therapeutics CPH ApS.
As of October 17, 2022, Søren Sylvester Skjærbæk is registered as liquidator of Dragonfly Therapeutics CPH ApS.
As of October 17, 2022, Gary Arthur Martell has stepped down as adm. dir. of Dragonfly Therapeutics CPH ApS.
On October 17, 2022, Dragonfly Therapeutics CPH ApS entered liquidation.
Dragonfly Therapeutics CPH ApS has published its interim report for the period July 29, 2020 – December 31, 2021.
As of May 16, 2022, RSM DANMARK STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Dragonfly Therapeutics CPH ApS.
As of September 30, 2020, Esper Boel has left the board of directors of Dragonfly Therapeutics CPH ApS.
As of September 30, 2020, Gary Arthur Martell has left the board of directors of Dragonfly Therapeutics CPH ApS.
As of September 30, 2020, Peter Andreas Nicolai Reumert Wagtmann has left the board of directors of Dragonfly Therapeutics CPH ApS.
As of September 30, 2020, Gary Arthur Martell is registered as adm. dir. of Dragonfly Therapeutics CPH ApS.
As of September 30, 2020, Esper Boel has stepped down as adm. dir. of Dragonfly Therapeutics CPH ApS.
As of July 29, 2020, Esper Boel has joined the board of directors of Dragonfly Therapeutics CPH ApS.
As of July 29, 2020, Gary Arthur Martell has joined the board of directors of Dragonfly Therapeutics CPH ApS.
As of July 29, 2020, Peter Andreas Nicolai Reumert Wagtmann has joined the board of directors of Dragonfly Therapeutics CPH ApS.
As of July 29, 2020, Esper Boel is registered as adm. dir. of Dragonfly Therapeutics CPH ApS.
Dragonfly Therapeutics CPH ApS was founded on July 29, 2020.
